Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions
Authors' conclusion
The endocrine signature of early PCOS is herewith extended to include modestly raised levels of circulating TSH; the normalizing effects of SPIOMET intervention in nonobese adolescents with PCOS are herewith extended to include on- and posttreatment TSH.
Study context
- Population
- Nonobese adolescents with polycystic ovary syndrome (PCOS)PCOS
- Participants
- 62 adolescents
- Comparison
- Oral contraceptive (OC) vs spironolactone-pioglitazone-metformin (SPIOMET) in nonobese adolescents with PCOS; PCOS vs controls
Methodological detailsrandomized pilot studies
- Randomized pilot studies
Primary result
As reported in the abstract
Morning TSH
- Mean thyroid-stimulating hormone (TSH) higher in PCOS than control girls
- On-treatment TSH remained elevated on OC and descended swiftly on SPIOMET, well into safe preconception range
- PCOS vs Controls: P < 0.01
- OC vs SPIOMET: P < 0.001
Further findings
Posttreatment TSH · 1 year posttreatment
- Posttreatment TSH stable in both subgroups
Association of on-treatment TSH changes with liver fat changes
- R
- 0.307
- p
- P = 0.017
Original publication
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions. Horm Res Paediatr. Published 17 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →